Science

Autoimmune diseases, such as lupus and myasthenia gravis, occur when the immune system mistakenly attacks the body.

There are more than
80
Autoimmune diseases
Impacting approximately
10%
of the global population

Cell Therapies

Cell therapies are treatments that use cells from the patient or a donor to repair or replace damaged cells and tissues, helping the body restore normal function or enhance its ability to fight diseases.

  • 1

    Patient / Donor T Cells

  • 2

    Reprogrammed T Cell

  • 3

    Infusion Into Patient

Current cell therapies have been helpful in treating certain types of cancer, but the application had not been used for autoimmune diseases. Current treatments require patients to undergo chemotherapy before starting, typically performed in a hospital. This can lead to challenges related to side effects, complexity during treatment, and high costs.

mRNA Cell Therapy

Leveraging new mRNA technologies, Cartesian’s mission is to extend the potential of cell therapy to patients with autoimmune diseases.

mRNA cell therapy is a new class of therapy that is designed to blend some of the best features of conventional nanoparticle-based mRNA therapy with existing cell therapies. Using this approach, Cartesian’s pipeline has the potential to expand the reach of this powerful modality to autoimmune conditions.

Proprietary Platform

Leveraging its proprietary platform, Cartesian’s internally manufactured portfolio of mRNA cell therapy candidates are purposefully designed to overcome several key limitations that have prevented the application of existing cell therapies for the treatment of autoimmune diseases. Cartesian’s product candidates have the potential to be dosed more reliably and safely in an outpatient setting without pretreatment chemotherapy.

No Lymphodepletion

No associated cytopenia, secondary malignancies, or other chemotherapy toxicities

Administered Outpatient

Convenient dosing schedule

Delivered at Therapeutic Levels

Administered at therapeutic doses without uncontrollable proliferation

Transient Cell Modification

Does not carry risk of genomic integration

Manufacturing

Cartesian operates a wholly owned, state-of-the-art current good manufacturing practice (cGMP) compliant facility in Frederick, Maryland. The facility has both clinical and commercial manufacturing scale capabilities designed to support Cartesian’s maturing pipeline of innovative mRNA cell therapies for the treatment of autoimmune diseases.

Publications & Presentations